Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366765 | 0.74 | GAA (0.34) | AHRCYP1A2ALDH1A1 | |
| SCHEMBL2969026 | 0.73 | ESR1 (0.41) | ALDH1A1ELANECYP3A4MAPT | |
| SCHEMBL6467371 | 0.71 | CHRNB2 (0.33) | — | |
| SCHEMBL6465925 | 0.69 | CHRNB2 (0.45) | ALDH1A1ATMELANE | |
| SCHEMBL1027276 | 0.67 | ALDH1A1 (0.34) | ALDH1A1MAPT | |
| SCHEMBL4738248 | 0.66 | — | — | |
| SCHEMBL12360750 | 0.62 | AHR (0.52) | AHRCYP1A2ALDH1A1ATMCYP2A6 | |
| SCHEMBL546371 | 0.62 | CYP1A2 (0.42) | AHRCYP1A2ALDH1A1ATMCYP2A6 | |
| SCHEMBL2336588 | 0.62 | CYP1A2 (0.41) | AHRCYP1A2ALDH1A1ATMCYP2A6 | |
| SCHEMBL293803 | 0.60 | CYP1A2 (0.41) | AHRCYP1A2ALDH1A1ATMCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203482-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | Bridgestone Corporation (JP) | 2010-07-07 | — | — | EP | claimed |
| WO-2009051702-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2009-04-23 | — | — | WO | claimed |
| WO-2009051700-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (US) | 2009-04-23 | — | — | WO | claimed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | claimed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| EP-3458488-A1 | PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS | Bridgestone Corporation (JP) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201397-A1 | PROCESS FOR PRODUCING FUNCTIONALIZED POLYMERS | BRIDGESTONE CORPORATION (JP) | 2017-11-23 | — | — | WO | disclosed |
| EP-2678327-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | Lupin Limited (IN) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012114285-A9 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012114285-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2012-08-30 | — | — | WO | disclosed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | AHR 1081/4885CYP1A2 103/4885ALDH1A1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.